Implications for teacher education as adult development

The authors believe that the issues addressed in this article will strongly impact the shape of integrated education in the future

Development of a chemically defined medium for optimal growth and recombinant protein production in HEK293 cells

The human cell line Human Embryonic Kidney (HEK) 293 is a popular workhorse for transient gene expression. Due to stringent regulatory requirement, better batch-to-batch consistency and simplified downstream processing, the demand for a chemically defined (CD) medium to support the growth of these cells is higher than ever. To address this need, Kerry has developed an animal component-free (ACF), chemically defined (CD) cell culture medium, to support the growth of HEK293 cells in suspension culture. AmpliHEK CD medium was designed from the knowledge gained in developing a medium for Chinese Hamster Ovary (CHO) cells and was refined by analysis of spent medium after growth of HEK293 cells in shake flasks to determine the nutrients needed for optimal growth. AmpliHEK is a versatile medium providing optimal cell culture conditions for the production of recombinant proteins, monoclonal antibodies and viral vectors. AmpliHEK medium formulation shows similar growth profile and viability compared to competitor CD media during and after sequential adaption. The medium also showed prolonged culture longevity and higher peak cell density in a batch culture (with glucose feeding), which is important for a higher production yield. The efficacy of this medium to support the expression of recombinant β-galactosidase in transient transfection was tested and found to be comparable with competitor CD media. Currently, the versatility of this medium using different HEK293 host cells is being tested. The effect of CD and complex feeds containing plant-based hydrolysates on transient gene expression was another scope of this study. In all, these results show that this medium could be used for industrial production with HEK293 cells

Implications of feeds and supplements on the productivity and quality of recombinant proteins produced in CHO cells

Chinese Hamster Ovary (CHO) cells have become the preferred host for recombinant protein production due to their ability to secrete desired proteins with post-translational modifications similar to those observed in humans. Biopharmaceutical companies routinely utilize supplements and feed systems for maximizing the yield of recombinant proteins in processes involving CHO cells. Although high productivity is desirable for monoclonal antibodies (mAbs) production, utilizing supplements and feeds might affect the quality of recombinant proteins. Clinical efficacy and safety of recombinant proteins is dependent on key quality attributes including glycosylation pattern, aggregates, charge variants and low molecular weight species. Our work outlines the comparison of productivity and quality of recombinant proteins produced in fed-batch CHO-cell based processes using commercially available chemically defined (CD) medium for CHO cells, CD feeds and a variety of complex supplements and feed systems. The CD medium, feeds and supplements were tested in three CHO cell lines, each expressing a different IgG molecule. Each cell line was sequentially adapted to all the different CD medium being evaluated. Multiple fed-batch experiments were performed in shake-flasks with combinations of different commercially available supplements and feeds. At regular intervals, samples were assessed for viable cell density, cell viability, nutrient metabolism and IgG titers for the different conditions. The key IgG quality attributes including glycosylation pattern, aggregates, charge variants, low molecular weight species were also evaluated for the samples obtained at the end of the fed-batch process. The medium/feed combinations which demonstrated high protein productivity and high cell viability at the end of the culture process were further tested in bioreactors to evaluate scalability of the medium/feed combinations in the different cell lines. The use of CD medium with either CD feed or complex feed supplements resulted in higher cell viability at the end of the fed-batch process in addition to higher IgG titers. After evaluation of the product quality, the desired glycosylation pattern was obtained in certain combinations of medium, supplements and feeds. Lower amount of IgG aggregation was also observed. Due to the unique nutritional requirements of each cell line, different combinations of medium/supplement/feed were needed for optimal cell growth and productivity without affecting the product quality

c-Myc regulates transcriptional pause release

Recruitment of the RNA polymerase II (Pol II) transcription initiation apparatus to promoters by specific DNA-binding transcription factors is well recognized as a key regulatory step in gene expression. We report here that promoter-proximal pausing is a general feature of transcription by Pol II in mammalian cells and thus an additional step where regulation of gene expression occurs. This suggests that some transcription factors recruit the transcription apparatus to promoters, whereas others effect promoter-proximal pause release. Indeed, we find that the transcription factor c-Myc, a key regulator of cellular proliferation, plays a major role in Pol II pause release rather than Pol II recruitment at its target genes. We discuss the implications of these results for the role of c-Myc amplification in human cancer.National Institutes of Health (U.S.) (Grant number RO1-HG002668)National Institutes of Health (U.S.) (Grant number RO1-GM34277)National Institutes of Health (U.S.) (Grant number RO1-CA133404)National Cancer Institute (U.S.) (Grant Number PO1- CA42063)National Cancer Institute (U.S.) Cancer Center Support Grant (Grant Number P30-CA14051)National Institutes of Health (U.S.) Postdoctoral Fellowship (5-F32-HD051190

Profiling the DNA-binding specificities of engineered Cys2His2 zinc finger domains using a rapid cell-based method

The C2H2 zinc finger is the most commonly utilized framework for engineering DNA-binding domains with novel specificities. Many different selection strategies have been developed to identify individual fingers that possess a particular DNA-binding specificity from a randomized library. In these experiments, each finger is selected in the context of a constant finger framework that ensures the identification of clones with a desired specificity by properly positioning the randomized finger on the DNA template. Following a successful selection, multiple zinc-finger clones are typically recovered that share similarities in the sequences of their DNA-recognition helices. In principle, each of the clones isolated from a selection is a candidate for assembly into a larger multi-finger protein, but to date a high-throughput method for identifying the most specific candidates for incorporation into a final multi-finger protein has not been available. Here we describe the development of a specificity profiling system that facilitates rapid and inexpensive characterization of engineered zinc-finger modules. Moreover, we demonstrate that specificity data collected using this system can be employed to rationally design zinc fingers with improved DNA-binding specificities

MicroRNA-34a Modulates c-Myc Transcriptional Complexes to Suppress Malignancy in Human Prostate Cancer Cells

MicroRNA-34a (miR-34a), a potent mediator of tumor suppressor p53, has been reported to function as a tumor suppressor and miR-34a was found to be downregulated in prostate cancer tissues. We studied the functional effects of miR-34a on c-Myc transcriptional complexes in PC-3 prostate cancer cells. Transfection of miR-34a into PC-3 cells strongly inhibited in vitro cell proliferation, cell invasion and promoted apoptosis. Transfection of miR-34a into PC-3 cells also significantly inhibited in vivo xenograft tumor growth in nude mice. miR-34a downregulated expression of c-Myc oncogene by targeting its 3′ UTR as shown by luciferase reporter assays. miR-34a was found to repress RhoA, a regulator of cell migration and invasion, by suppressing c-Myc–Skp2–Miz1 transcriptional complex that activates RhoA. Overexpression of c-Myc reversed miR-34a suppression of RhoA expression, suggesting that miR-34a inhibits invasion by suppressing RhoA through c-Myc. miR-34a was also found to repress c-Myc-pTEFB transcription elongation complex, indicating one of the mechanisms by which miR-34a has profound effects on cellular function. This is the first report to document that miR-34a suppresses assembly and function of the c-Myc–Skp2–Miz1 complex that activates RhoA and the c-Myc-pTEFB complex that elongates transcription of various genes, suggesting a novel role of miR-34a in the regulation of transcription by c-Myc complex

HEXIM1 is a promiscuous double-stranded RNA-binding protein and interacts with RNAs in addition to 7SK in cultured cells

P-TEFb regulates eukaryotic gene expression at the level of transcription elongation, and is itself controlled by the reversible association of 7SK RNA and an RNA-binding protein HEXIM1 or HEXIM2. In an effort to determine the minimal region of 7SK needed to interact with HEXIM1 in vitro, we found that an oligo comprised of nucleotides 10–48 sufficed. A bid to further narrow down the minimal region of 7SK led to a surprising finding that HEXIM1 binds to double-stranded RNA in a sequence-independent manner. Both dsRNA and 7SK (10–48), but not dsDNA, competed efficiently with full-length 7SK for HEXIM1 binding in vitro. Upon binding dsRNA, a large conformational change was observed in HEXIM1 that allowed the recruitment and inhibition of P-TEFb. Both subcellular fractionation and immunofluorescence demonstrated that, while most HEXIM1 is found in the nucleus, a significant fraction is found in the cytoplasm. Immunoprecipitation experiments demonstrated that both nuclear and cytoplasmic HEXIM1 is associated with RNA. Interestingly, the one microRNA examined (mir-16) was found in HEXIM1 immunoprecipitates, while the small nuclear RNAs, U6 and U2, were not. Our study illuminates novel properties of HEXIM1 both in vitro and in vivo, and suggests that HEXIM1 may be involved in other nuclear and cytoplasmic processes besides controlling P-TEFb

Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid

Small non-coding RNAs of 18–25 nt in length can regulate gene expression through the RNA interference (RNAi) pathway. To characterize small RNAs in HIV-1-infected cells, we performed linker-ligated cloning followed by high-throughput pyrosequencing. Here, we report the composition of small RNAs in HIV-1 productively infected MT4 T-cells. We identified several HIV-1 small RNA clones and a highly abundant small 18-nt RNA that is antisense to the HIV-1 primer-binding site (PBS). This 18-nt RNA apparently originated from the dsRNA hybrid formed by the HIV-1 PBS and the 3′ end of the human cellular tRNAlys3. It was found to associate with the Ago2 protein, suggesting its possible function in the cellular RNAi machinery for targeting HIV-1

Mediator Subunit 12 Is Required for Neutrophil Development in Zebrafish

Hematopoiesis requires the spatiotemporal organization of regulatory factors to successfully orchestrate diverse lineage specificity from stem and progenitor cells. Med12 is a regulatory component of the large Mediator complex that enables contact between the general RNA polymerase II transcriptional machinery and enhancer bound regulatory factors. We have identified a new zebrafish med12 allele, syr, with a single missense mutation causing a valine to aspartic acid change at position 1046. Syr shows defects in hematopoiesis, which predominantly affect the myeloid lineage. Syr has identified a hematopoietic cell-specific requirement for Med12, suggesting a new role for this transcriptional regulator

Proviral HIV-genome-wide and pol-gene specific Zinc Finger Nucleases: Usability for targeted HIV gene therapy

<p>Abstract</p> <p>Background</p> <p>Infection with HIV, which culminates in the establishment of a latent proviral reservoir, presents formidable challenges for ultimate cure. Building on the hypothesis that <it>ex-vivo </it>or even <it>in-vivo </it>abolition <it>or </it>disruption of HIV-gene/genome-action by target mutagenesis or excision can irreversibly abrogate HIV's innate fitness to replicate and survive, we previously identified the isoschizomeric bacteria restriction enzymes (REases) AcsI and ApoI as potent cleavers of the HIV-pol gene (11 and 9 times in HIV-1 and 2, respectively). However, both enzymes, along with others found to cleave across the entire HIV-1 genome, slice (SX) at palindromic sequences that are prevalent within the human genome and thereby pose the risk of host genome toxicity. A long-term goal in the field of R-M enzymatic therapeutics has thus been to generate synthetic restriction endonucleases with longer recognition sites limited in specificity to HIV. We aimed (i) to assemble and construct zinc finger <it>arrays </it>and <it>nucleases </it>(ZFN) with either proviral-HIV-pol gene or proviral-HIV-1 whole-genome specificity respectively, and (ii) to advance a model for pre-clinically testing lentiviral vectors (LV) that deliver and transduce either ZFN genotype.</p> <p>Methods and Results</p> <p><it>First, </it>we computationally generated the consensus sequences of (a) 114 dsDNA-binding zinc finger (Zif) <it>arrays </it>(ZFAs or Zif_HIV-pol) and (b) two zinc-finger <it>nucleases </it>(ZFNs) which, unlike the AcsI and ApoI homeodomains, possess specificity to >18 base-pair sequences uniquely present within the HIV-pol gene (Zif_HIV-polF_N). Another 15 ZFNs targeting >18 bp sequences within the complete HIV-1 proviral genome were constructed (Zif_HIV-1F_N). <it>Second, </it>a model for constructing lentiviral vectors (LVs) that deliver and transduce a diploid copy of either Zif_HIV-polF_Nor Zif_HIV-1F_Nchimeric genes (termed <b>LV- 2xZif</b>_{<b>HIV-pol</b>}<b>F</b>_{<b>N </b>}and <b>LV- 2xZif</b>_<b>HIV-1</b><b>F</b>_{<b>N, </b>}respectively) is proposed. <it>Third, </it>two preclinical models for controlled testing of the safety and efficacy of either of these LVs are described using active HIV-infected TZM-bl reporter cells (HeLa-derived JC53-BL cells) and latent HIV-infected cell lines.</p> <p>Conclusion</p> <p><b>LV-2xZif</b>_{<b>HIV-pol</b>}<b>F</b>_{<b>N </b>}and <b>LV- 2xZif</b>_<b>HIV-1</b><b>F</b>_{<b>N </b>}may offer the <it>ex-vivo </it>or even <it>in-vivo </it>experimental opportunity to halt HIV replication functionally by directly abrogating HIV-pol-gene-action <it>or </it>disrupting/excising over 80% of the proviral HIV DNA from latently infected cells.</p